

**Stephen G. Emerson, MD, PhD, Director, The Herbert Irving Comprehensive Cancer Center at New York-Presbyterian Hospital/Columbia University Medical Center.**

Dr. Emerson is the Clyde and Helen Wu Professor of Immunology (in Medicine), Professor of Microbiology and Immunology, and the Director of the Herbert Irving Comprehensive Cancer Center (HICCC). Dr. Emerson received his BA from Haverford College in 1974 and his MS, PhD and MD from Yale University in 1980, before going on to train in Internal Medicine at the Massachusetts General Hospital and in Hematology/Oncology at the Brigham and Women's Hospital and the Dana-Farber Cancer Institute. Beginning with purification of human hematopoietic stem cells as a postdoctoral fellow, Dr. Emerson has made significant contributions to our understanding of hematopoiesis and its regulation by the immune system, many of which have clinically translated into stem cell transplantation for the treatment of cancer. A member of the American Society for Clinical Investigation and the American Academy of Pediatrics, he has served extensively on NIH study sections and journal editorial boards, most recently as Deputy and Senior Editor of the Journal of Clinical Investigation; he also chaired the Scientific Programs of both the American Society of Hematology and the American Society of Blood and Marrow Transplantation. He has been recognized with many awards including the Leukemia and Lymphoma Society's Stohlman Prize, the Wilbur Cross Medal from Yale University, and Knighthood from the French Legion of Honor.

Before joining Columbia, Dr. Emerson served, from 1994-2007, as Chief of the Division of Hematology/Oncology (in Medicine) and Associate Director for Clinical and Translational Research at the Abramson Cancer Center of the University of Pennsylvania. During this time, the Division grew in terms of size, programmatic reach, and funding, with a 10-fold increase in its peer-reviewed funding portfolio. Dr. Emerson established, via recruitment, training and support, new programs in allogeneic transplantation and immunotherapy, cancer genetics, and molecularly targeted therapeutics, and started the first Penn/Children's Hospital of Philadelphia K12 research training and career development program. From 2007-2012, Dr. Emerson served as President of his alma matter, Haverford College, where he developed new programs in local, regional and international student service and research, and he took on national leadership roles in leveraging undergraduate training to increase the national pipeline of bench and translational physician scientists.

Since joining CUMC in 2012, and taking over directorship of the HICCC, Dr. Emerson has launched Center-wide strategic planning, yielding new forward-looking priorities, invested in key Cancer Center Shared Resources and recruited top leaders in basic, translational, and clinical research from across all fields of cancer, building bridges between research and clinical care. Through his leadership and extensive experience in building and integration of matrix-based Comprehensive Cancer Centers, integration of research and training, and the scientific mission and policies of the National Cancer Institute, the HICCC has continued to grow in excellence and innovation. The Center now has eight research programs, 17 Shared Resource core and more than 260 members, who are researchers and physicians dedicated to understanding the biology of cancer and to applying that knowledge to the design of cancer treatment and prevention strategies. HICCC's goal is to reduce cancer incidence and progression and improve the quality of the lives of those affected by cancer by caring through innovation with all the possibilities of modern medicine.